Filter posts

Analysis and Impact of PDUFA V

As the House of Representatives voted unanimously to approve legislation to approve the Prescription Drug …

BIO 2012 Super Session Recap: Burrill State-of-the-Industry Report

“How are we doing? It’s tough.” That’s what G. Steven Burrill, CEO of Burrill & …

Cancer Research Pioneer Dr. Margaret Foti named 2012 Biotech Humanitarian Honoree

Today, BIO named Dr. Margaret Foti, , Ph.D., M.D. (h.c.), CEO of the American Association …

Americans, Biotech Execs, Convention Attendees Optimistic About Biotech

What does the future hold for biotechnology? After surveying American voters, biotech executives, and attendees …

An Insider’s View of the BioGENEius Challenge

By Erica Hiar, Environics A big highlight every year for many attendees at BIO International …

What’s the Buzz?

Meet Deuteria Pharmaceuticals, winner of the 2012 Buzz of BIO competition. What is Buzz of …

BIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders

The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the …

Prior User Rights and Trade Secrets

By Joe Allen, President, Allen and Associates One theme of the day is the cloud …

Recent Developments in Patentability: Prometheus and Myriad

By Joe Allen, President, Allen and Associates Recent Developments in Patentability: Prometheus and Myriad at …

From Bench to Bedside in a Bioeconomy

By Joe Allen, President, Allen and Associates It’s a sign of a well crafted program …